HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

PSI 352938

inhibits HCV NS5B polymerase; structure in first source

Also Known As:

GS-0938; PSI-352938; PSI352938

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Heterocyclic Oxides
  - Cyclic P-Oxides
    - PSI 352938: 4
Carbohydrates: 22023
- Glycosides: 2119
  - Nucleosides: 6847
    - PSI 352938: 4
Nucleic Acids, Nucleotides, and Nucleosides: 1
- Nucleosides: 6847
  - PSI 352938: 4

Experts

1.	De Clercq, Erik: 1 article (06/2014)
2.	Denning, Jill: 1 article (01/2014)
3.	Guedj, Jeremie: 1 article (01/2014)
4.	Lawitz, Eric: 1 article (01/2014)
5.	Pang, Phillip S: 1 article (01/2014)
6.	Perelson, Alan S: 1 article (01/2014)
7.	Rodriguez-Torres, Maribel: 1 article (01/2014)
8.	Symonds, William: 1 article (01/2014)
9.	Berrey, M M: 1 article (10/2013)
10.	Cornpropst, M T: 1 article (10/2013)

Related Diseases

1.	Hepatitis C 01/01/2014 - "Analysis of hepatitis C viral kinetics during administration of two nucleotide analogues: sofosbuvir (GS-7977) and GS-0938." 10/01/2013 - "All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (nuclear)." 06/15/2014 - "The direct-acting antivirals (DAAs) currently in development for treatment of hepatitis C fall into four categories: (i) NS3/4A protease inhibitors: ABT-450/r, faldaprevir, asunaprevir, GS-9256, vedroprevir (GS-9451), danoprevir, MK-5172, vaniprevir, sovaprevir, ACH-2684, narlaprevir and simeprevir, in addition to those that are already developed [telaprevir (Incivek®) and boceprevir (Victrelis®)], (ii) NS5A protein inhibitors: ABT-267, daclatasvir, ledipasvir, ACH-2928, ACH-3102, PPI-668, AZD-7295, MK-8742, and GSK 2336805; (iii) NS5B (nucleoside-type) polymerase inhibitors: sofosbuvir (now approved by the FDA since 6 December 2013), GS-0938, mericitabine, VX-135, ALS 2158 and TMC 649128; (iv) NS5B (non-nucleoside-type) polymerase inhibitors: VX-222, ABT-072, ABT-333, deleobuvir, tegobuvir, setrobuvir, VCH-916, VCH-759, BMS-791325 and TMC-647055. "
2.	Infections 05/20/2011 - "PSI-352938 is a novel 2'-deoxy-2'-α-fluoro-2'-β-C-methyl 3',5'-cyclic phosphate nucleotide prodrug currently under investigation for the treatment of hepatitis C virus (HCV) infection. "

Related Drugs and Biologics

1.	Sofosbuvir
2.	Nucleotides
3.	Proteins (Proteins, Gene)
4.	Phosphates (Orthophosphate)
5.	Nucleosides
6.	Antiviral Agents (Antivirals)
7.	ProTides
8.	HCV NS3-4A Protease Inhibitors
9.	Simeprevir
10.	dasabuvir

Related Therapies and Procedures

1.	Therapeutics